MedTrace Logo

Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

NCT04499859 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3548

Last updated 2025-07-30

No results posted yet for this study

Summary

Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.

This trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and ezetimibe among patients with acute myocardial infarction who went through percutaneous coronary intervention at decreasing major adverse cardiac events compared to the efficacy of single use of high dose rosuvastatin.

Conditions

Interventions

DRUG

Ezetimibe 10mg + Rosuvastatin 5mg

Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin

DRUG

Rosuvastatin 20mg

20mg of Rosuvastatin as a standard treatment for AMI patients

Sponsors & Collaborators

  • Kiyuk Chang, MD,PhD

    lead OTHER

Principal Investigators

  • Kiyuk Chang, MD,PhD · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2026-08-30
Completion
2027-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499859 on ClinicalTrials.gov